Figure 1From: A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer Serum CA125 in the four confirmed (202, 208, 219, 228) and one unconfirmed (220) responding or stabilizing patients including the period of pretrial evaluation. Cvac treatments began on day 1 and are indicated as (â–²). The day of withdrawal from the trial is indicated as (â—‹), except for patients 219 and 228 where data are truncated at 12 months.Back to article page